Gamze Aslan1, Saide Aytekin2. 1. Department of Cardiology, Koc University School of Medicine and Hospital, Maltepe Mah., Topkapı Cad. No: 4, 34010, Zeytinburnu, Istanbul, Turkey. gaslan@kuh.ku.edu.tr. 2. Department of Cardiology, Koc University School of Medicine and Hospital, Maltepe Mah., Topkapı Cad. No: 4, 34010, Zeytinburnu, Istanbul, Turkey.
Abstract
INTRODUCTION: Urocortin 2 (UCN2), is an endogenous stress-related peptide belonging to the corticotropin-releasing factor (CRF) family, has a major role in the pathogenesis of congestive heart failure, ischemic heart disease, and hypertension. AIM: To investigate the role of UCN2 levels in patients with hypertension (HTN). METHODS: Serum UCN2 levels measured by ELISA were compared between patients with HTN (n = 86) and nonHTN (n = 53). RESULTS: Eighty-six patients with HTN [median age 66 (45-76); 38 men] and 53 patients with non-HTN [median age 62 (40-80); 39 men] were included into this study. Serum UCN2 (5.17 ng/ml; IQR, 1.26-11.68 ng/ml vs 0.79 ng/ml; IQR, 0.07-4.10 ng/ml, p < 0.0005) levels were found significantly elevated in patients with HTN compared to nonHTN control group. Concentrations of serum UCN2 were positively correlated with left ventricle mass index to body surface area (LV mass index to BSA, r = 0.20, p = 0.03), LV mass index to height2.7 (r = 0.28, p = 0.002) and body mass index (r = 0.24, p = 0.008). Additionally, logistic regression analysis was performed to UCN2, uric acid, creatinine, glomerular filtration rate, age, body mass index, coronary artery disease and diabetes mellitus which are the potential confounders of hypertension. According to logistic regression analysis serum UCN2 values were found out as an independent predictor of HTN. CONCLUSION: UCN2 levels, correlated with LV mass index were increased in HTN patients compared to nonHTN patients. These data provide evidence that there could be a relationship between high concentrations of UCN2 and HTN. UCN2 may appear as a promising choice of HTN treatment in the future.
INTRODUCTION:Urocortin 2 (UCN2), is an endogenous stress-related peptide belonging to the corticotropin-releasing factor (CRF) family, has a major role in the pathogenesis of congestive heart failure, ischemic heart disease, and hypertension. AIM: To investigate the role of UCN2 levels in patients with hypertension (HTN). METHODS: Serum UCN2 levels measured by ELISA were compared between patients with HTN (n = 86) and nonHTN (n = 53). RESULTS: Eighty-six patients with HTN [median age 66 (45-76); 38 men] and 53 patients with non-HTN [median age 62 (40-80); 39 men] were included into this study. Serum UCN2 (5.17 ng/ml; IQR, 1.26-11.68 ng/ml vs 0.79 ng/ml; IQR, 0.07-4.10 ng/ml, p < 0.0005) levels were found significantly elevated in patients with HTN compared to nonHTN control group. Concentrations of serum UCN2 were positively correlated with left ventricle mass index to body surface area (LV mass index to BSA, r = 0.20, p = 0.03), LV mass index to height2.7 (r = 0.28, p = 0.002) and body mass index (r = 0.24, p = 0.008). Additionally, logistic regression analysis was performed to UCN2, uric acid, creatinine, glomerular filtration rate, age, body mass index, coronary artery disease and diabetes mellitus which are the potential confounders of hypertension. According to logistic regression analysis serum UCN2 values were found out as an independent predictor of HTN. CONCLUSION:UCN2 levels, correlated with LV mass index were increased in HTNpatients compared to nonHTN patients. These data provide evidence that there could be a relationship between high concentrations of UCN2 and HTN. UCN2 may appear as a promising choice of HTN treatment in the future.
Authors: E Dermitzaki; C Tsatsanis; V Minas; E Chatzaki; I Charalampopoulos; M Venihaki; A Androulidaki; M Lambropoulou; J Spiess; E Michalodimitrakis; A Gravanis; A N Margioris Journal: Endocrinology Date: 2006-12-28 Impact factor: 4.736
Authors: Li-Zhen Yang; Jens Kockskämper; Shelina Khan; Jorge Suarez; Stefanie Walther; Bernhard Doleschal; Gregor Unterer; Mounir Khafaga; Heinrich Mächler; Frank R Heinzel; Wolfgang H Dillmann; Burkert Pieske; Joachim Spiess Journal: Br J Pharmacol Date: 2011-01 Impact factor: 8.739
Authors: Kristof Van Kolen; Frank M Dautzenberg; Karin Verstraeten; Ines Royaux; Ronald De Hoogt; Eric Gutknecht; Pieter J Peeters Journal: Neuropharmacology Date: 2009-06-30 Impact factor: 5.250
Authors: Thomas Dieterle; Silvia Meili-Butz; Katrin Bühler; Christian Morandi; Dietlinde John; Peter T Buser; Jean Rivier; Wylie W Vale; Kirk L Peterson; Marijke Brink Journal: Hypertension Date: 2009-02-09 Impact factor: 10.190
Authors: Tracy L Bale; Masahiko Hoshijima; Yusu Gu; Nancy Dalton; Keith R Anderson; Kuo-Fen Lee; Jean Rivier; Kenneth R Chien; Wylie W Vale; Kirk L Peterson Journal: Proc Natl Acad Sci U S A Date: 2004-02-27 Impact factor: 11.205
Authors: Zhengrong Hao; Yan Huang; Jake Cleman; Ion S Jovin; Wylie W Vale; Tracy L Bale; Frank J Giordano Journal: Proc Natl Acad Sci U S A Date: 2008-02-28 Impact factor: 11.205
Authors: Elena Grossini; Claudio Molinari; David A S G Mary; Paolo Marino; Giovanni Vacca Journal: Eur J Pharmacol Date: 2007-10-02 Impact factor: 4.432
Authors: Elena Grossini; Claudio Molinari; David A S G Mary; Francesca Uberti; Flavio Ribichini; Philippe Primo Caimmi; Giovanni Vacca Journal: Cell Physiol Biochem Date: 2009-02-18